Ion Channel Mutations
Definition
Genetic variants in genes encoding cardiac ion channels (or associated proteins) that alter channel function, producing either gain-of-function (increased current) or loss-of-function (decreased current) effects. These mutations underlie all primary cardiac channelopathies.
Key Concepts
- Gain-of-function mutations increase channel activity. In Na⁺ channels (SCN5A), this prolongs depolarization/plateau → LQT3. In K⁺ channels (KCNH2, KCNQ1, KCNJ2), this accelerates repolarization → SQTS. In K⁺ channels (KCNJ8/ABCC9, KCND3), this increases Ito or IK-ATP → BrS, ERS. (sources/channelopathies-jaha-2025)
- Loss-of-function mutations decrease channel activity. In K⁺ channels (KCNQ1, KCNH2), reduced IKs/IKr delays repolarization → LQTS. In Na⁺ channels (SCN5A), reduced INa slows conduction → BrS. In Ca²⁺ channels (CACNA1C, CACNB2, CACNA2D1), reduced ICa,L shortens plateau → BrS, SQTS, ERS. (sources/channelopathies-jaha-2025)
- Mutations may affect channel gating, conformation, drug-binding sites, trafficking, or interactions with intracellular regulators, which influences how channels respond to drugs — creating the rationale for genotype-guided therapy. (sources/channelopathies-jaha-2025)
- Some genes (e.g., SCN5A) can produce different channelopathies depending on whether the mutation is gain- or loss-of-function: gain-of-function → LQT3; loss-of-function → BrS. (sources/channelopathies-jaha-2025)
- Non-ion-channel proteins can also be implicated: ankyrin B (ANK2/LQT4) causes abnormal ion channel localization; plakophilin-2 (PKP2) affects INa and is linked to both BrS and CPVT. (sources/channelopathies-jaha-2025)
- Variants of uncertain significance (VUS) are common in genetic testing and add complexity to diagnosis and risk stratification. (sources/channelopathies-jaha-2025)
Contradictions / Open Questions
- Same gene, opposite phenotypes (SCN5A): GOF SCN5A mutations cause LQT3 (prolonged QT, torsades de pointes); LOF mutations cause Brugada syndrome (short-coupled VF). The same gene, via opposite mutation effects, produces phenotypically and therapeutically contradictory diseases. Accurate direction-of-effect characterization for each variant is critical before treatment — a GOF drug applied to a LOF SCN5A variant would worsen the phenotype. (sources/channelopathies-jaha-2025)
- VUS prevalence limits clinical utility: Variants of uncertain significance are common in genetic testing for channelopathies. A VUS in KCNQ1 or KCNH2 does not distinguish between benign population variation and a rare pathogenic cause of LQTS. The clinical majority of individuals tested receive a VUS result that provides neither reassurance nor a clear management pathway. (sources/channelopathies-jaha-2025)
Connections
- Related to concepts/Cardiac-Action-Potential
- Related to concepts/Sudden-Cardiac-Death
- Related to entities/SCN5A
- Related to entities/RYR2
- Related to entities/KCNQ1
- Related to entities/KCNH2
- Related to entities/Long-QT-Syndrome
- Related to entities/Brugada-Syndrome
- Related to entities/CPVT